ANOVA-Based Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer with Bone Metastasis and Rehabilitation Treatment

Abstract

This study was to analyze the magnetic resonance imaging (MRI) characteristics of prostate cancer patients with bone metastasis and the difference in the rehabilitation effect of patients with different bone metastases. The MRI, diffusion weighted imaging (DWI), magnetic resonance elastic imaging (MRE), and MRI + DWI + MRE imaging were performed on 200 prostate cancer patients in the First Affiliated Hospital of Kunming Medical University hospital. The prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA), and prostate volume in patients with bone metastases were analyzed. The sensitivity, specificity, and accuracy of the four detection methods of bone metastases in prostate cancer were detected. In addition, the changes of the bone metabolism index β-special collagen sequence (β-CTX), type I procollagen amino terminal propeptide (PINP), and osteocalcin (BGP) of the patients were analyzed and compared before and after the treatment. The results showed that the levels of PSMA4 (17.35 ± 51.64 ng/mL) and PSA (15.86 ± 6.33 ng/mL) in nonbone metastatic prostate cancer patients were much lower than those of osteogenic bone metastases (668.95 ± 47.13 ng/mL and 202.15 ± 31.53 ng/mL), mixed bone metastases (637.63 ± 41.35 ng/mL and 186.45 ± 24.86 ng/mL) prostate patients. The sensitivity (96.25%), specificity (89.85%), and accuracy (98.53%) of MRI + DWI + MRE in the prostate cancer bone metastasis were obviously higher than those of MRI (86.46%, 78.31%, and 90.31%), DWI (88.11%, 82.53%, and 91.43%), and MRE (83.36%, 76.94%, and 89.76%). The levels of β-CTX (0.41 ± 0.07 ng/mL), PINP (39.04 ± 6.38 ng/mL), and BGP (17.56 ± 4.22 ng/mL) after treatment in patients with nonbone metastasis prostate cancer were greatly lower than those of osteogenic bone metastases (0.66 ± 0.08 ng/mL, 51.45 ± 7.45 ng/mL, and 33.65 ± 6.14 ng/mL) and patients with mixed bone metastases (0.75 ± 0.12 ng/mL, 53.66 ± 9.22 ng/mL, and 31.24 ± 5.73 ng/mL), showing statistically obvious differences ( P < 0.05 ). In short, the sensitivity, specificity, and accuracy of MRI + DWI + MRE in detection of prostate cancer bone metastasis were better than those of a single examination method, showing significant impacts on the rehabilitation of patients with prostate cancer bone metastasis.